Ivim Health GLP-1 Program: Structure, Eligibility, Pathway

This article is part of the PlexusDx Education Hub, a library of evidence-based guidance on GLP-1 therapies, weight-management protocols, and the genetic factors that shape metabolic care. Browse all Peptides & GLP-1 education

This is an independent editorial review. PlexusDx has no commercial relationship with Ivim Health, uses no affiliate links, and receives no compensation from the brand.

"Ivim Health GLP-1" usually points to one thing: the company GLP-1 weight-management program and how it moves a patient from intake to a dispensed medication. This single-brand review focuses on program mechanics, eligibility, and the compounded-pharmacy pathway, then notes the one input a telehealth program cannot supply. It is fair-balance editorial context as of April 2026, not a buying recommendation.

What Ivim Health is

Ivim Health operates as telehealth paired with a compounded-pharmacy pathway. In this model a licensed provider evaluates the patient virtually and can route a prescription either to a retail pharmacy for a branded FDA-approved product or to a 503A compounding pharmacy for compounded semaglutide or tirzepatide. Current structure and pricing sit on the Ivim Health website.

How the GLP-1 program runs step by step

The typical flow: a patient submits an intake covering weight, history, and current medications; a clinician reviews it and, if criteria are met, issues a prescription; the order routes to a retail or 503A compounding pharmacy; and telehealth follow-up supports dose titration and side-effect management. Variations show up in provider type and pharmacy partner rather than the overall arc.

Eligibility and clinical screening

Eligibility hinges on the clinical review, not the checkout page. Providers weigh factors such as weight metrics, medical history, and contraindications before prescribing. A program that screens meaningfully is doing its job; the screening is what separates a legitimate telehealth pathway from a storefront that simply dispenses on request.

What the pricing depends on

Published pricing lives on the brand own site and turns on the product chosen (semaglutide versus tirzepatide), the subscription tier, and whether the medication is branded or compounded. Because these variables and the numbers themselves change frequently, verify current pricing on the Ivim Health website before committing.

The compounds and their evidence base

Whatever the program, the pharmacology comes from the compound class: GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual GIP/GLP-1 agonist tirzepatide. Trial anchors include STEP (semaglutide, NEJM 2021), SURMOUNT (tirzepatide, NEJM 2022), and SURMOUNT-OSA (NEJM 2024). Populations and endpoints vary, and individual outcomes vary too. A telehealth brand can select which of these compounds it offers and how it supports titration, but it cannot rewrite the evidence attached to the molecule, which is why the program you choose matters less than the compound and dose you and your provider settle on.

The genetic context Ivim does not map

A telehealth program can prescribe a compound but cannot read the biology receiving it. Variants in GLP1R, the GLP-1 receptor gene that every compound in this class targets, along with FTO and MC4R, define the metabolic baseline a protocol enters. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, describing that baseline without predicting response to any specific medication.

Pairing a protocol with genetic insight

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, including Semaglutide Injection ($189/month), Semaglutide Oral, Tirzepatide Injection ($289/month), and Tirzepatide Oral. Starting with the Precision Peptide Genetic Test adds the upstream context a telehealth-only program does not include.

Not affiliated: PlexusDx has no commercial relationship with Ivim Health or any other brand named here.

Keep reading on PlexusDx: GLP-1 Hormone, What Is GLP-1, GLP-1 What Is, GLP-1 Receptor Agonist.

Editorial note: this review is educational. PlexusDx sells semaglutide and tirzepatide through its own Weight Management Protocols and is unaffiliated with Ivim Health. The Precision Peptide Genetic Test reports genetic influence on peptide pathways and does not predict medication response. Consult a qualified provider before starting any protocol.

Frequently Asked Questions

What does the Ivim Health GLP-1 program actually include?

It generally includes a virtual clinical evaluation, a provider-issued prescription when eligibility is met, dispensing through a retail or 503A compounding pharmacy, and telehealth follow-up for titration and side effects. The exact features and tiers are published on the brand own site and can change over time.

Who is eligible for the program?

Eligibility is decided during clinical review based on weight metrics, medical history, and contraindications rather than at checkout. A meaningful screening step is a marker of a legitimate telehealth pathway, so expect a provider to assess suitability before any prescription is issued.

How much does the Ivim Health GLP-1 program cost?

Pricing is published on the brand website and depends on the medication chosen, the subscription tier, and whether the product is branded or compounded. Numbers change frequently, so confirm the current figures directly on the Ivim Health site before making a commitment.

Does genetic testing change how the program works?

No. The Precision Peptide Genetic Test does not alter the program or predict response to a compound. It maps variants such as GLP1R and FTO that describe your baseline GLP-1 biology, context that applies regardless of which telehealth service ultimately prescribes the medication.

This article belongs to the PlexusDx Education Hub. Browse all Peptides & GLP-1 education